Journal Article Epublish
PubMed: 40149637 DOI: 10.3390/biomedicines13030661
Multi-Omics Analysis of the Anoikis Gene in Prostate Cancer and Biochemical Recurrence (BCR).
Biomedicines 13(3)
Authors: Shan Huang, Hang Yin
Affiliations
- Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Institute of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100034, China.
Abstract
Prostate cancer, as an androgen-dependent malignant tumor in older men, has attracted the attention of a wide range of clinicians. BCR remains a significant challenge following early prostate cancer treatment. The specific expression pattern of the Anoikis gene set in prostate cancer cells was first explored by single-cell and spatial transcriptomics analysis. Genes causally associated with prostate cancer were screened using Summary-data-based Mendelian Randomization (SMR). Subsequently, we explored the role and mechanism of in prostate cancer cells and defined a new cell type: the T cell. We constructed a prediction model that can better predict the BCR of prostate cancer, and explored the differences in various aspects of clinical subgroups, tumor microenvironments, immune checkpoints, drug sensitivities, and tumor-immune circulations between high- and low-risk groups. The results of SMR analysis indicated that could increase the risk of prostate cancer. Based on the differential genes of -positive and -negative T cells, we constructed a four-gene prognostic model with a 5-year AUC of 0.713. The results revealed that high-risk prostate cancer BCR patients had various characteristics such as higher tumor purity, higher BCR rate, downregulated SIRPA immune checkpoints, and unique drug sensitivity. In summary, may be a potential biomarker for prostate cancer.
MeSH
Cells, Genes, Pharmaceutical Preparations, Neoplasms, Multiple Chronic Conditions, Prostate, Anoikis, Prostatic Neoplasms